Related Experiment Video

Updated: Jan 17, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.4K

Approaches for treating cardiovascular symptoms in Parkinson's disease

Wolfgang H Jost1, Jiri Koschel2

  • 1Parkinson-Klinik Ortenau, Kreuzbergstraße 12-16, Wolfach 77709, Germany.

Therapeutic Advances in Neurological Disorders
|September 19, 2025
PubMed

Insights

Cardiovascular symptoms are common in Parkinson's disease (PD). This review covers current therapies for cardiovascular diseases (CVD) in PD patients, focusing on managing autonomic dysfunction and reducing CVD risk.

Area of Science:

  • Neurology
  • Cardiology
  • Geriatrics

Background:

  • Cardiovascular symptoms are prevalent in Parkinson's disease (PD), manifesting as non-motor symptoms (NMS) or coexisting cardiovascular diseases (CVD).
  • Autonomic dysfunction in PD frequently leads to blood pressure abnormalities, including orthostatic hypotension, postprandial hypotension, and supine hypertension (SH).
  • The elderly population is disproportionately affected by both PD and CVD, increasing the complexity of diagnosis and treatment.

Purpose of the Study:

  • To review the current therapeutic strategies for cardiovascular diseases (CVD) in patients with Parkinson's disease (PD).
  • To highlight the challenges in diagnosing and treating cardiovascular symptoms in PD patients, particularly those with autonomic dysfunction.
  • To emphasize the importance of prophylactic measures for cardiovascular risk reduction in PD.

Main Methods:

  • Literature review of studies on cardiovascular disease (CVD) therapy in Parkinson's disease (PD).
  • Analysis of research concerning autonomic dysfunction and blood pressure issues in PD.
  • Examination of prophylactic strategies and polypharmacy considerations in PD patients with CVD.

Main Results:

  • Cardiovascular symptoms, including autonomic dysfunction and atherosclerotic vascular diseases like stroke and myocardial infarction, are common in PD.
  • Managing blood pressure issues such as orthostatic hypotension and supine hypertension (SH) is crucial.
  • PD patients often require polypharmacy, complicating treatment regimens.

Conclusions:

  • Effective management of cardiovascular diseases (CVD) in Parkinson's disease (PD) requires addressing autonomic dysfunction and implementing prophylactic measures.
  • The review synthesizes current therapeutic approaches for CVD in PD, offering insights into state-of-the-art treatments.
  • Integrated care strategies are essential for optimizing outcomes in elderly PD patients with coexisting CVD.

Keywords:
Parkinson’s diseasecardiovascular symptomsorthostatic hypotension

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

23.0K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.0K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
447